Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.92
-0.07 (-0.78%)
Mar 3, 2026, 4:00 PM EST - Market closed

Emergent BioSolutions Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
742.91,0441,0491,1181,774
Revenue Growth (YoY)
-28.81%-0.54%-6.10%-36.99%12.45%
Cost of Revenue
326.2681.3705.4693.1748.1
Gross Profit
416.7362.3343.9424.41,026
Selling, General & Admin
186.1308368.4339.5348.7
Depreciation & Amortization Expenses
65.165.165.659.958.5
Research & Development
53.270.7111.4188.3235.2
Other Operating Expenses
12.227.2524.96.741.7
Total Operating Expenses
316.64711,070594.4684.1
Operating Income
100.1-108.7-726.4-170341.4
Interest Expense
-59.3-71-87.9-37.3-34.5
Other Non-Operating Income (Expense)
66.436.883.1-11.7-3.7
Total Non-Operating Income (Expense)
7.1-34.2-4.8-49-38.2
Pretax Income
82.8-142.9-731.2-219303.2
Provision for Income Taxes
30.247.729.3-7.483.7
Net Income
52.6-190.6-760.5-211.6219.5
Net Income to Common
52.6-190.6-760.5-211.6219.5
Net Income Growth
-----28.22%
Shares Outstanding (Basic)
5453515054
Shares Outstanding (Diluted)
5753515054
Shares Change (YoY)
6.98%3.52%2.20%-7.39%0.56%
EPS (Basic)
0.98-3.60-14.85-4.224.10
EPS (Diluted)
0.93-3.60-14.85-4.224.06
EPS Growth
-----28.52%
Free Cash Flow
156.835.8-257.9-149.996.1
Free Cash Flow Growth
337.99%----75.67%
Free Cash Flow Per Share
2.770.68-5.04-2.991.78
Gross Margin
56.09%34.72%32.77%37.98%57.82%
Operating Margin
13.47%-10.42%-69.23%-15.21%19.25%
Profit Margin
7.08%-18.26%-72.48%-18.94%12.38%
FCF Margin
21.11%3.43%-24.58%-13.41%5.42%
EBITDA
205.77.5-580-22.6469.3
EBITDA Margin
27.69%0.72%-55.27%-2.02%26.46%
EBIT
100.1-108.7-726.4-170341.4
EBIT Margin
13.47%-10.42%-69.23%-15.21%19.25%
Effective Tax Rate
36.47%-33.38%-4.01%3.38%27.61%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q